Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC Ponatinib (AP24534) 943319-70-8 10mM (in 1mL DMSO)
Supplier: Apexbio Technology LLC A54675.1
Ponatinib (AP24534 CAS 943319-70-8) is a second-generation small molecule inhibitor targeting the BCR-ABL fusion kinase The BCR-ABL fusion arising from a t(9 22) chromosomal translocation encodes oncogenic tyrosine kinase variants implicated in chronic myeloid leukemia (CML) acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) Ponatinib inhibits both wild-type BCR-ABL (IC50 0 5 nM) and resistant mutants notably the T315I mutant (IC50 11 nM) Additionally it potently inhibits clinically relevant kinases such as RET FLT3 KIT PDGFR / and FGFR1 Ponatinib is utilized in cancer biology research pertaining to kinase-driven malignancies
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?